<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Ophidian Pharmaceuticals, Inc.
------------------------------
(Name of Issuer)
Common Stock, $.0025 Par Value
------------------------------
(Title of Class of Securities)
683725105
---------
(CUSIP Number)
N/A
---
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
___ Rule 13d-1(b)
___ Rule 13d-1(c)
X Rule 13d-1(d)
---
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
Page 1 of 5 Pages
<PAGE>
CUSIP No. 683725105
(1) Name of Reporting Person: Eli Lilly and Company
I.R.S. Identification 35-0470950
No. of Above Person
(2) Check the Appropriate Box (a) [_]
if a Member of a Group (b) [_]
Not Applicable
(3) SEC Use Only
(4) Citizenship or Place of Indiana
Organization
Number of Shares (5) Sole Voting 699,300
Beneficially Owned Power
by Each Reporting (6) Shared Voting None
Person With Power
(7) Sole Dispositive 699,300
Power
(8) Shared Disposi- None
tive Power
(9) Aggregate Amount Beneficially 699,300
Owned by Each Reporting Person
(10) Check if the Aggregate Amount Not Applicable
In Row (9) Excludes Certain Shares
(11) Percent of Class Represented 7.6%
by Amount in Row (9)
(12) Type of Reporting Person CO
Page 2 of 5 Pages
<PAGE>
Item 1(a). Name of Issuer:
Ophidian Pharmaceuticals, Inc.
Item 1(b). Address of Issuer's Principal
Executive Offices:
5445 East Cheryl Parkway
Madison, WI 53711
Item 2(a). Name of Person Filing:
Eli Lilly and Company
Item 2(b). Address of Principal Business
Office or, if None, Residence:
Lilly Corporate Center
Indianapolis, IN 46285
Item 2(c). Citizenship:
Indiana
Item 2(d). Title of Class of Securities:
Common Stock, $.0025 Par Value
Item 2(e). CUSIP Number:
683725105
Item 3. If this statement is filed pursuant to Rule 13d-1(b), or
13d-2(b) or (c), check whether the person filing is a:
(a)-(j) Not applicable
If this statement is filed pursuant to Rule 13d-1(c), check
this box. [_]
Page 3 of 5 Pages
<PAGE>
Item 4. Ownership.
(a) Amount Beneficially Owned:
699,300
(b) Percent of Class:
7.6%
(c) Number of shares as to which the person has:
Sole voting power 699,300
Shared voting power None
Sole dispositive power 699,300
Shared dispositive power None
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable
Item 6. Ownership of More Than Five Percent on Behalf
of Another Person.
Not applicable
Item 7. Identification and Classification of the Subsidiary
which Acquired the Security Being Reported on by
the Parent Holding Company.
Not applicable
Item 8. Identification and Classification of Members of the Group.
Not applicable
Item 9. Notice of Dissolution of Group.
Not applicable
Page 4 of 5 Pages
<PAGE>
Item 10. Certifications.
Not applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
ELI LILLY AND COMPANY
By: /s/ Charles E. Golden
---------------------------------------
Charles E. Golden
Executive Vice President and
Chief Financial Officer
Date: February 11, 1999
Page 5 of 5 Pages
